Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tevard Biosciences
Headquarters: Cambridge, MA, United States of America
Website: https://tevard.com/
Year Founded: 2017
Status: Private
BioCentury | Jun 26, 2024
Management Tracks
Arvinas, Frontier name new CFOs
Plus: Audrey Duval to lead corporate affairs at Sanofi, and updates from MOMA,
BioCentury | Nov 15, 2023
Management Tracks
CFO Fox moving on from Nuvation
Plus: Nucleome hires Harrison as CSO, and updates from Senisca, HaemaLogiX and Tevard
BioCentury | Sep 21, 2023
Emerging Company Profile
hC Bio: restoring protein function with tRNA therapies
Its sights set on cancer and rare diseases, Boston-based hC Bioscience hopes to take its first engineered tRNA therapy into the clinic next year
BioCentury | Jun 24, 2023
Discovery & Translation
ROTACs for transmembrane protein degradation; plus AntlerA’s lung regeneration therapy and more
BioCentury’s roundup of translational news
BioCentury | Nov 9, 2021
Emerging Company Profile
Alltrna: Creating the tRNA modality
Flagship’s latest RNA company Alltrna aims to pioneer tRNA therapies
BioCentury | Oct 23, 2021
Product Development
Gene therapy’s next class of biotechs
And the innovative technologies they’re developing
BioCentury | May 12, 2021
Deals
MiNA leads in RNA therapeutics deals : Data Byte
A small activating RNA partnership with Lilly gives MiNA the largest deal count and total disclosed deal value for RNA therapeutics, defined as therapies that deliver or stimulate production of RNA,
BioCentury | Dec 5, 2020
Product Development
Dec. 4 Quick Takes: Zogenix in Dravet deal with start-up; plus updates from BioCryst, Takeda, AB Science, Sutro, Lilly, Cedars-Sinai
Aiming to reverse Dravet, Tevard partners with ZogenixZogenix Inc. (NASDAQ:ZGNX) will collaborate with Tevard Biosciences to develop transfer RNA-based gene therapies to treat Dravet syndrome and
Items per page:
1 - 8 of 8